A Multicenter, Randomized, Double-Blind, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-Dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation.

Trial Profile

A Multicenter, Randomized, Double-Blind, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-Dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Idrabiotaparinux sodium (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms BOREALIS-AF
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Mar 2014 Results published in the Journal of Thrombosis and Haemostasis.
    • 26 Oct 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 04 Mar 2010 Status changed from active, no longer recruiting to suspended as reported by Clinical Trials Registry - India.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top